Print Icon

Next Generation Proteomics Highlights

Dear Subscriber, 

We are excited to share the latest updates and news from and around Biognosys and our research services with you:

Biognosys’ Cambridge (MA) Office Inauguration Event on October 13

Last May, we opened an office in Cambridge, Massachusetts, a global biopharma hub. A milestone we want to mark with a big inauguration event featuring presentations by Biognosys’ experts, as well as collaborators NeoGenomics, Takeda, and Kymera. The event will conclude with a ribbon-cutting ceremony and consecutive champagne mixer with live music.

Biognosys Poster Presentations and Exhibition at ESMO ’22

We cannot wait to share with you the data we generated in collaboration with NeoGenomics, University of Zurich, and IRCCS Istituto Nazionale Tumori Fondazione G. Pascale. Furthermore, you will be able to learn about our next-generation proteomics platforms, offering transformative insights from discovery to clinic for oncology research. Stop by booth no. 433, we will be there!

Biognosys Co-authored Nature Communications Publication on HR-LiP

Have you read our publication in collaboration with the University of Cambridge and AstraZeneca that shows how a compound binding to VCP D1 ATPase enhances proteasomal neurotoxic protein clearance? Our High Resolution Limited Proteolysis (HR-LiP) technology was used to 3D-map the binding site and explain the observed phenotype.

Accessing Multi-dimensional Biological Insights Through MS Proteomics

Proteomics has the potential to optimize drug development and improve clinical care. In this article in collaboration with Thermo Fisher Scientific, our CEO, Oliver Rinner, PhD, and Andreas Huhmer, PhD, discuss the opportunities and advancements of mass spectrometry (MS) for high-throughput proteomics.

How Targeted Proteomics is Taking the Clinical Assay Market by Storm

Our Chief Technology Officer, Lukas Reiter, PhD, shares insights on how the sensitivity of mass spectrometry-based targeted proteomics exponentially increased in the past years and how much that can impact research from discovery to clinic.

Visit our website to learn more about how we can support your proteomics research, and stay tuned for more exciting news to come.

Best regards, 
The Biognosys Team

Can't read or view images? View in Browser

Not interested? Unsubscribe

No more? Opt Out from Organization